CDD-2789

Overview

CDD-2789 is a potent and selective ALK2 inhibitor with an IC 50 0.54 μM and a K d of 2.1 nM, respectively. CDD-2789 exhibits >120-fold selectivity over ALK3/5/6 . CDD-2789 reduces activin A- and BMP2 -induced SMAD1/5 phosphorylation in fibroblasts. CDD-2789 can be used for ALK2-related cancer research.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > TGF-β Receptor

Product Information

• Catalog No.: HY-173149
• CAS No.: 3052084-77-9
• Molecular Formula: C26H34N4O4
• Molecular Weight: 466.57
• Purity: 99.98%
• Storage: Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (10.72 mM); Clear solution
• Availability: In-stock

Source

Original product source